Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal

European spine journal

article

Stefano Boriani¹  Riccardo Cecchinato¹  Fabrizio Cuzzocrea²  Stefano Bandiera³  Marco Gambarotti⁴  Alessandro Gasbarrini³ 

[1] IRCCS Istituto Ortopedico Galeazzi;University Department of Orthopedics;Department of Pathology, IRCCS Istituto Ortopedico Rizzoli;Department of Oncologic and Degenerative Spine Surgery, IRCCS Istituto Ortopedico Rizzoli

关键词: Giant cell tumor;    Spine;    Denosumab;    En bloc resection;    Spondylectomy;   

DOI  :  10.1007/s00586-019-05997-0

来源: Springer

【 摘 要 】

The interest on the role of Denosumab in the treatment strategy of giant cell tumor of the spine is growing. En bloc resection is considered the Enneking appropriate treatment, but morbidity and functional loss are sometimes unacceptable. Denosumab could play a role as a stand-alone treatment, but also as preoperative treatment or as postoperative after intralesional surgery. A cohort of 10 out of 12 cases of spinal GCT consecutively treated with Denosumab are analyzed and discussed compared to the cases reported in the literature. A staging of the radiological effect of the treatment is proposed. The stand-alone and postoperative treatments are still running (12 to 88 months). One therapy was stopped after 15 months, once a satisfactory local effect was achieved, but the treatment had to be restarted 2 months later due to the recurrence of the erosive images. The new treatment was successful. At 1-year follow-up after the gross total excision followed by postoperative Denosumab treatment, no evidence of local recurrence was found. The preoperative treatment duration ranged from 3 to 24 months. No local recurrence followed the en bloc resections. Denosumab alone is effective in relieving pain, increasing the ossification and sometimes reducing the tumor volume. It can be considered an excellent solution in spine GCTs whose surgical treatment cannot be Enneking appropriate or is associated with unacceptable morbidity or loss of functions. It is still impossible to state when to safely stop the treatment. Denosumab also plays a role as preoperative protocol. These slides can be retrieved under Electronic Supplementary Material.

【 授权许可】

Unknown